Retinopathy of prematurity: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Retinopathy of prematurity: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

  • 182 Pages | 26-Oct-17 | Format:PDF | Last Updated: Updation in process
  • “GervanoRA’s pipeline analysis and opportunity assessment report “Retinopathy of prematurity: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018” analyzed and assessed Retinopathy of prematurity pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Retinopathy of prematurity industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Epidemiology and Epidemiology forecast 2018 – 2025
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Patent Analysis of Pipeline Molecules
    • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities
    Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.”

  • “TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. EXECUTIVE SUMMARY
    2.1. REPORT MAJOR FINDINGS
    2.2. KEY EVENTS IN RETINOPATHY OF PREMATURITY COMPETITIVE SPACE
    3. DISEASE OVERVIEW
    3.1. DISEASE DEFINITION & SYMPTOMS
    3.1.1. CLINICAL MANIFESTATIONS
    3.1.2. PATHOGENESIS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHM AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    3.6. EPIDEMIOLOGY FORECAST
    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4. MARKET DYNAMICS
    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    4.2. PRICING AND REIMBURSEMENT
    4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
    4.5. NEW DRUG APPROVALS (EX-US) SINCE 2010
    4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    5. PIPELINE ANALYSIS
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. RETINOPATHY OF PREMATURITY PHASE 3 MOLECULES
    5.1.2. RETINOPATHY OF PREMATURITY PHASE 2 MOLECULES
    5.1.3. RETINOPATHY OF PREMATURITY PHASE 1 MOLECULES
    5.1.4. RETINOPATHY OF PREMATURITY PRECLINICAL MOLECULES
    5.1.5. RETINOPATHY OF PREMATURITY EARLY R&D MOLECULES
    5.1.6. RETINOPATHY OF PREMATURITY INACTIVE AND DISCONTINUED MOLECULES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6. PIPELINE MOLECULES BY UNIVERSITIES AND INSTITUTES
    6. ESTIMATED APPROVAL TIMELINE
    6.1.1. METHODOLOGY
    6.1.2. ESTIMATED APPROVAL TIME LINES US & EX-US
    7. RETINOPATHY OF PREMATURITY CLINICAL TRIALS SUMMARY
    7.1. RETINOPATHY OF PREMATURITY PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
    7.1.1. KEY PHASE 3 RESULTS
    7.1.2. KEY PHASE 2 RESULTS
    7.2. ONGOING CLINICAL TRIALS SUMMARY
    7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
    7.3. PLANNED CLINICAL TRIALS SUMMARY
    7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
    7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
    7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
    8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    8.1. COMPANIES
    8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
    8.1.2. TOP 20 EMERGING COMPANIES IN THE RETINOPATHY OF PREMATURITY AREA
    8.3. UNIVERSITIES AND INSTITUTES – LICENSING OPPORTUNITIES
    9. ABBREVIATIONS
    LIST OF TABLES:
    TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
    TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
    TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE RETINOPATHY OF PREMATURITY AREA
    TABLE 04: MAJOR LICENSING AGREEMENTS IN THE RETINOPATHY OF PREMATURITY AREA
    TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE RETINOPATHY OF PREMATURITY AREA
    TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE RETINOPATHY OF PREMATURITY AREA
    TABLE 07: MAJOR FINANCING DEALS IN THE RETINOPATHY OF PREMATURITY AREA
    TABLE 08: MAJOR DEALS IN THE RETINOPATHY OF PREMATURITY AREA RANKED BY DEAL AMOUNT
    TABLE 09: US FDA APPROVED DRUGS SINCE 2010
    TABLE 10: EX-US APPROVED DRUGS SINCE 2010
    TABLE 11: PHASE 3 MOLECULES IN THE RETINOPATHY OF PREMATURITY DRUG PIPELINE
    TABLE 12: PHASE 2 MOLECULES IN THE RETINOPATHY OF PREMATURITY DRUG PIPELINE
    TABLE 13: PHASE 1 MOLECULES IN THE RETINOPATHY OF PREMATURITY DRUG PIPELINE
    TABLE 14: PRECLINICAL MOLECULES IN THE RETINOPATHY OF PREMATURITY DRUG PIPELINE
    TABLE 15: EARLY R&D MOLECULES IN THE RETINOPATHY OF PREMATURITY DRUG PIPELINE
    TABLE 16: INACTIVE AND DISCONTINUED MOLECULES IN THE RETINOPATHY OF PREMATURITY DRUG PIPELINE
    TABLE 17: RETINOPATHY OF PREMATURITY PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
    TABLE 18: RETINOPATHY OF PREMATURITY PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
    TABLE 19: RETINOPATHY OF PREMATURITY PIPELINE MOLECULES BY UNIVERSITIES
    TABLE 20: RETINOPATHY OF PREMATURITY PIPELINE MOLECULES BY INSTITUTES
    TABLE 21: ESTIMATED APPROVAL Time lines OF PIPELINE MOLECULES
    TABLE 22: KEY PHASE 3 ONGOING CLINICAL TRIALS
    TABLE 23: KEY PHASE 2 ONGOING CLINICAL TRIALS
    TABLE 24: KEY PHASE 1 ONGOING CLINICAL TRIALS
    TABLE 25: PLANNED CLINICAL TRIALS FOR THE RETINOPATHY OF PREMATURITY AREA
    TABLE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
    TABLE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
    TABLE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
    TABLE 29: ESTABLISHED COMPANIES SCENARIO
    TABLE 30: LIST OF EMERGING COMPANIES IN THE RETINOPATHY OF PREMATURITY AREA
    TABLE 31: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
    TABLE 32: COMPETITIVE OPPORTUNITIES, INSTITUTES
    (Above mentioned tables are a few among the total 91 tables in the report)
    LIST OF FIGURES:
    FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
    FIGURE 02: RETINOPATHY OF PREMATURITY EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
    FIGURE 03: OVERALL DEALS ACTIVITY IN THE RETINOPATHY OF PREMATURITY AREA
    FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
    FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
    FIGURE 06: RETINOPATHY OF PREMATURITY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
    FIGURE 07: RETINOPATHY OF PREMATURITY DRUG PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 08: RETINOPATHY OF PREMATURITY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
    FIGURE 09: RETINOPATHY OF PREMATURITY DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    FIGURE 10: RETINOPATHY OF PREMATURITY DRUG PIPELINE ANALYSIS BY DRUG CLASS
    FIGURE 11: RETINOPATHY OF PREMATURITY PIPELINE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
    FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
    FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
    FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
    FIGURE 15: COMPANY FINANCIAL INFORMATION
    FIGURE 16: COMPANY SWOT ANALYSIS
    (Above mentioned figures are a few among the total 45 figures in the report)”

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)